Our preclinical results provide a strong rationale for randomized studies comparing osimertinib vs osimertinib plus chemotherapy, either in EGFR T790M positive and also in EGFR-TKI naïve NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.